Global TradFi & Macroeconomics

Focus on price action and volatility across stocks, bonds, forex, commodities, and major indices. Analyze macro indicators like interest rates, inflation, employment, and policy expectations to decode global liquidity shifts, risk sentiment, and cross-market correlations.
All
Stocks
Metals
Indices
Forex
Commodities

Capricor Stocks Rise 7% as FDA Extends Deramiocel Review to November

Capricor Therapeutics (CAPR) shares rose nearly 7% on Monday after the U.S. Food and Drug Administration extended its review of the biotech firm's experimental Duchenne muscular dystrophy treatment, Deramiocel, by three months. The FDA postponed the therapy's decision date from August 22 to
GateMacroTradfiHub·08-24 15:14
Capricor Stocks Rise 7% as FDA Extends Deramiocel Review to November

FDA Extends CAPR's Deramiocel Review by Three Months to November 22

According to the FDA, on August 24, Capricor Therapeutics (CAPR) had its Deramiocel review extended by three months, with the decision deadline moved from August 22 to November 22. The FDA accepted a major amendment including 24-month follow-up data from the Phase 3 Hope-3 study focused on
GateNews·08-24 15:13
FDA Extends CAPR's Deramiocel Review by Three Months to November 22

Cox Capital Expands Liquidity Program to $131 Billion Interval Fund Market

Cox Capital Partners plans to extend its private-market liquidity program from non-traded business development companies into interval funds, offering investors another way to sell holdings when a fund's scheduled repurchase program cannot meet all withdrawal requests. An affiliate intends to
GateMacroTradfiHub·08-24 15:13
Cox Capital Expands Liquidity Program to $131 Billion Interval Fund Market